BEN-MAIMON CAROLE purchased $50K of LRMR

BEN-MAIMON CAROLE (President and CEO) purchased 18,050 shares of Larimar Therapeutics, Inc. (LRMR) at $2.77 on 2026-11-11.

Original reporting
SEC EDGAR · BEN-MAIMON CAROLE
Published Nov 12, 2026, 11:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LRMR
Bullish
medium confidence
Mentioned
$LRMR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRMRBullishLow
01

Why it matters

The filing adds a new data point on insider sentiment for LRMR but is unlikely to move the stock significantly.

02

Market read

A small insider purchase that provides a modest bullish cue but limited trading relevance.

03

What to watch

Potential upcoming clinical milestones that prompted the insider to increase holdings.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$LRMRBullishMedium confidence
Context

CEO Carole Ben-Maimon bought 18,050 shares at $2.7675 each, totaling $49,953, increasing her stake to 386,326 shares.

Expected impact

modest upward pressure as market may view the buy as a positive signal

Evidence & confidence

The transaction is a primary Form 4 filing, but the $50K size is small relative to market cap, limiting price impact.

Market effects

Minimal; biotech sector may note insider confidence but no broader effect.

None; limited to LRMR shareholders.

None

Counterpoint

The purchase could be routine portfolio rebalancing, not a strong endorsement.

Key entities

  • Larimar Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

  • Carole Ben‑Maimon

    President and CEO of Larimar Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.